Haematological malignancies

Gene: MSH2

Green List (high evidence)

MSH2 (mutS homolog 2, Ensemblv90)
EnsemblGeneIds (GRCh38): ENSG00000095002
EnsemblGeneIds (GRCh37): ENSG00000095002
OMIM: 609309, ClinGen, DECIPHER
MSH2 is in 1 panel

1 review

Bryony Thompson (Royal Melbourne Hospital)

Green List (high evidence)

Haematological malignancies can be a feature of biallelic MMR deficiency
Created: 7 Feb 2026, 6:04 p.m. | Last Modified: 7 Feb 2026, 6:04 p.m.
Panel Version: 0.44

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
Mismatch repair cancer syndrome 2, MONDO:0030840

Publications

Details

Mode of Inheritance
BIALLELIC, autosomal or pseudoautosomal
Sources
  • Expert Review Green
  • Curated sources
Phenotypes
  • Class: Familial cancer syndrome
  • Constitutional mismatch repair deficiency
  • Lymphoma, ALL, MDS, AML
  • Brain tumors, gastrointestinal cancers, GI (colon), ovarian, uterine, CNS, other
OMIM
609309
ClinGen
MSH2
DECIPHER
MSH2
Clinvar variants
Variants in MSH2
Penetrance
None
Publications
Panels with this gene

History Filter Activity

Note: This information shows the history of the gene symbol, not the gene entity. Where the gene symbol for a gene has changed, this history may reference a different gene to the entry you are currently viewing.
7 Feb 2026, Gel status: 3

Entity classified by Genomics England curator

Bryony Thompson (Royal Melbourne Hospital)

Gene: msh2 has been classified as Green List (High Evidence).

7 Feb 2026, Gel status: 3

Created, Added New Source, Set mode of inheritance, Set publications, Set Phenotypes

Bryony Thompson (Royal Melbourne Hospital)

gene: MSH2 was added gene: MSH2 was added to Haematological malignancies cancer susceptibility. Sources: Curated sources,Expert Review Green Mode of inheritance for gene: MSH2 was set to BIALLELIC, autosomal or pseudoautosomal Publications for gene: MSH2 were set to 27881370; 28297620 Phenotypes for gene: MSH2 were set to Class: Familial cancer syndrome; Constitutional mismatch repair deficiency; Lymphoma, ALL, MDS, AML; Brain tumors, gastrointestinal cancers, GI (colon), ovarian, uterine, CNS, other